Brunner H R, Bidiville J, Waeber G, Porchet M, Nussberger J, Waeber B
Division of Nephrology and Hypertension, Centre Hospitalier Universitaire, Lausanne, Switzerland.
Nephron. 1987;47 Suppl 1:87-9. doi: 10.1159/000184560.
Sixteen patients with essential hypertension were treated for 2 consecutive 6-week periods with either the angiotensin-converting enzyme (ACE) inhibitor enalapril (20 mg once daily) or the calcium antagonist diltiazem (120 mg twice daily). The sequence of the treatment phases was randomly allocated. Blood pressure decreased from 154/102 +/- 5/2 mm Hg (mean +/- SEM) to 135/96 +/- 4/2 and 140/98 +/- 3/2 mm Hg during treatment with enalapril and diltiazem, respectively. It was impossible in the individual hypertensive patient to predict the long-term blood pressure response to one of the agents studied based on the long-term blood pressure response to the other agent.
16例原发性高血压患者连续接受两个为期6周的治疗阶段，分别使用血管紧张素转换酶（ACE）抑制剂依那普利（每日1次，20毫克）或钙拮抗剂地尔硫䓬（每日2次，120毫克）。治疗阶段的顺序是随机分配的。在使用依那普利和地尔硫䓬治疗期间，血压分别从154/102±5/2毫米汞柱（平均值±标准误）降至135/96±4/2和140/98±3/2毫米汞柱。对于个体高血压患者，不可能根据对另一种研究药物的长期血压反应来预测对其中一种药物的长期血压反应。
